Tarsus Pharmaceuticals, Inc. (TARS)

32.85 -1.57 (-4.56%) At close: 04:00PM EDT

Tarsus Pharmaceuticals, Inc.

15440 Laguna Canyon Road
Suite 160
Irvine, CA 92618
United States
949 409 1801
https://www.tarsusrx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 244

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Bobak R. Azamian M.D.	Co-Founder, President, CEO & Chairman	962.08k	N/A	N/A
Dr. Bryan Wahl J.D., M.D.	General Counsel & Corporate Secretary	619.09k	N/A	1978
Dr. Elizabeth Yeu Lin M.D.	Chief Medical Advisor & Director	286k	N/A	1978
Mr. Jeffrey S. Farrow	CFO & Chief Strategy Officer	N/A	N/A	1962
Dr. Seshadri Neervannan Ph.D.	Chief Operating Officer	486.67k	N/A	1968
Mr. David Nakasone	Head of Investor Relations	N/A	N/A	N/A
Ms. Adrienne Kemp	Senior Director of Corporate Communications	N/A	N/A	N/A
Mr. Matthew Rossen M.B.A.	Vice President of Marketing	N/A	N/A	1978
Mr. Scott Youmans	Vice President of Sales	N/A	N/A	N/A
Ms. Dianne C. Whitfield M.S.W.	Chief Human Resources Officer	578.9k	N/A	1977

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Corporate Governance

Tarsus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.